- Home
- HUIZ vs LPCN Comparison
HUIZ vs LPCN Comparison
Compare HUIZ & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HUIZ | LPCN |
|---|---|---|
| Founded | 2006 | 1997 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.8M | 19.1M |
| IPO Year | 2019 | 2011 |
Fundamental Metrics
Financial Performance| Metric | HUIZ | LPCN |
|---|---|---|
| Price | $1.49 | $2.35 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $2.30 | N/A |
| AVG Volume (30 Days) | 10.7K | ★ 187.9K |
| Earning Date | 06-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 46.18 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,976,677.00 |
| Revenue This Year | $8.58 | N/A |
| Revenue Next Year | $6.64 | $92.00 |
| P/E Ratio | $7.81 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.19 | $1.81 |
| 52 Week High | $4.16 | $12.37 |
Technical Indicators
Market Signals| Indicator | HUIZ | LPCN |
|---|---|---|
| Relative Strength Index (RSI) | 53.35 | 34.99 |
| Support Level | $1.60 | $2.20 |
| Resistance Level | $1.83 | $2.50 |
| Average True Range (ATR) | 0.14 | 0.11 |
| MACD | -0.00 | 0.18 |
| Stochastic Oscillator | 79.99 | 58.32 |
Price Performance
Historical ComparisonAbout HUIZ Huize Holding Limited
Huize Holding Ltd is an independent online insurance product and service platform in China. The company distributes on its platform insurance products underwritten by the insurance companies that cooperate with the company, which the company refers to as its insurer partners, and helps them reach a large number of insurance clients. The company's platform offers a digitalized insurance purchase experience and services through various internet and mobile internet channels. The company generates revenues from the insurance brokerage fees paid by its insurer partners.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.